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ABSTRACT
In 2018, cancer was reported to be the second top cause of morbidity and mortality 
globally with over 9 million deaths. Hematological malignancies including leukemia 
constitute about 7% of the total cancer cases. Substantial developments in treatment 
modalities and strategies have increased the 5-year survival rate in leukemia to 
around 60% in developed countries. However, complete remission and long-term 
disease control are not yet achieved. Oxidative stress is imprinted in many types of 
cancer including leukemia and represents a valuable trait for achieving leukemia-
selective cytotoxicity. The present thesis represents a systematic study of the role 
of redox-active selenocompounds (SeCs) in leukemia treatment.
Six diverse selenocompounds representing different compound classes were 
studied. Among them, p-xyelenselenocyanate (p-XSC) was shown to have the 
most potent cytotoxic activity against several leukemia cell lines carrying distinct 
oncogenes. p-XSC exerted its cytotoxicity in a concentration- and time-dependent 
manner. Mechanistic studies revealed that the cytotoxicity of p-XSC was mediated 
by upregulation of oxidative stress and accompanied with massive mitochondria 
 damages. Importantly, the cytotoxicity of SeCs was antagonized by albumin which 
is ubiquitously present in biological conditions. By the combination of two distinct, 
but complementary selenium speciation methods including liquid chromatography-
mass spectrometry and X-ray absorption spectroscopy, we showed that cytotoxic 
SeCs were capable of transforming into selenol intermediates that subsequently 
bound to albumin via selenium-sulfur bond. Furthermore, we found that the macro-
molecular selenocompound-albumin conjugate was also internalized and able to 
kill leukemia cells.
In addition to interfering with cytotoxicity, binding of SeCs to albumin also  hindered 
the quantification of these compounds in biological matrix e.g. plasma. To elucidate 
the pharmacokinetics properties of SeCs for in vivo applications, we developed a 
novel REductive Cleavage and Instant Derivatization (RECID) method, by which 
we were able to measure both free and albumin-bound SeCs. In the leukemia mouse 
model, intravenous administration of p-XSC was shown to reduce the disease 
 burden in whole body as well as in bone marrow.
In conclusion, the results obtained in the present thesis provide substantial experi-
mental evidences that redox-active SeCs, in particular p-XSC, possess high 
therapeutic potential as treatment for leukemia. Further investigations to optimize 
treatment regimen and to design an appropriate drug carrier are needed to achieve 
successful clinical trials. 
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11 INTRODUCTION
1.1 Leukemia
1.1.1 Definition of leukemia
Cancer is a collective name given to a number of related diseases in which  abnormal 
cells divide without control and can invade neighboring tissues. The malignant cells 
can spread to other parts of the body through the blood and lymphatic systems. 
Cancer can be classified according to two systems, either according to the tissue 
from where the cancer originates (histologically) or by primary site from where 
cancer starts. According to the histological classification, cancer could be classified 
into carcinoma, sarcoma, melanoma, myeloma, lymphoma, and leukemia. Leukemia 
is popularly known as “blood cancer” and arises from the outgrowth of abnormal 
white blood cell (WBC, also called leukocyte; Figure 1A).1 The large amounts of 
abnormal WBC do not form solid mass but primarily occupy bone marrow and blood. 
According to the rate of disease progression, leukemia can be divided into acute 
and chronic forms; while according to the cell lineage leukemia can be lymphoid 
or myeloid. Leukemia in general is further divided into four major categories: acute 
lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic 
leukemia (CLL) and chronic myeloid leukemia (CML). Integration of cytogenetic 
information on the top of morphological diagnosis has enabled finer classification 
of leukemia, particularly AML, and informed better clinical practices.1
1.1.2 Leukemia epidemiology and prognosis
According to the GLOBOCAN 2018, leukemia was newly diagnosed in 437 thousands 
(2.4% of all cancer cases) patients worldwide and resulted into 309 thousands (3.2% 
of all cases) deaths. The numbers are expected to increase till 656 and 491  thousands 
by 2040, respectively (Figure 1B).2 In the United States, the overall 5-year survival 
rate for leukemia has almost quadrupled during the period of 1960-2014 (from 14% 
till 65%); however, that for AML remains as low as 28%.3 The 5-year survival rate in 
Sweden is above 60% for all leukemia subtypes and around 25% for AML by 2016,4 
which is similar to that in the United States. In China, the estimated incidences and 
deaths in leukemia during 2015 were 75.3 and 53.4 thousands cases, respectively.5 
In sharp contrast, the 5-year survival rate for leukemia patients that were diagnosed 
by 2015 was as low as 25.4% (Figure 1C).6
21.2 Leukemia Treatment
1.2.1 Current treatments 
Several options are available for leukemia treatment including chemotherapy, 
radiotherapy, targeted therapy, and adoptive cell therapy. Chemotherapy uses 
cytostatics to eradicate leukemia cells directly and is currently the major form of 
treatment. Commonly used cytostatics could be categorized into antimetabolites, 
alkylating agents, antitumor antibiotics, vinca alkaloids and anti-microtubule agents. 
Chemotherapy alone or in combination with radiotherapy is used as neoadjuvant-, 
adjuvant- and consolidation-therapy in hematological diseases. In contrast to the 
long history of using the chemotherapy, targeted therapy is an emerging but power-
ful option that originates from better understandings of the cytogenetic features of 
Figure 1. Etiology, epidemiology and prognosis of leukemia
(A) Normal blood cells contain erythrocyte, platelet, and leukocyte. The overgrowth of 
abnormal and immature leukocyte that comprises lymphocyte, neutrophil, monocyte and 
eosinophil leads to development of leukemia. (B) Incidence of leukemia in 2018 and 2040 
worldwide.2 (C) 5-Year survival rate of leukemia and AML in USA, Sweden and China.3-6 
Panel A was reprinted with permission from Manu Sharma (https://www.scientificanimations.com/) 
and adapted.
3leukemia. In principle, it mainly affects leukemia cells that express certain target 
molecules, therefore off-target toxicity and/or the adverse effects are minimized.7 
Adoptive cell therapy relies on intravenous infusion of functional immune cells for 
cancer regression and treatment, with the best-known procedure being hematopoietic 
stem cell transplantation. Interestingly, the last decade has witnessed tremendous 
advances in clinical use of chimeric antigen receptor-expressing T cells which 
are genetically engineered ex vivo to empower more functionality, like specificity 
and persistence, for certain subtype of cancer.8 Cancer immunotherapy including 
checkpoint inhibitors and cytokines acts through mobilization of the patient’s own 
immune system (usually under suppression) for identifying and destroying cancer 
cells. In spite of the tremendous and long-lasting efficacy against solid tumor, 
clinical practice of checkpoint inhibitors is still limited in leukemia.9
1.2.2 Limitations of chemotherapy
Chemotherapy e.g. cytostatics are non-specific drugs, and they act on not only 
leukemia cells but also fast-proliferating healthy cells like gastrointestinal tract 
epithelial cells and hair follicle cells. The toxicity of cytostatic drugs on healthy 
cells eventually manifests as side effects, e.g. mucositis, nausea, loss of weight 
and appetite, anemia, alopecia, infection and fatigue.
Apart from the side effects, resistance to chemotherapy develops on basis of  intrinsic 
and adaptive machanisms.10 Some leukemia subpopulation including leukemic 
stem cells have low proliferation rate but high self-renewing and adaptive ability, 
thereby being less vulnerable to chemotherapy.11 The resistance is also endowed by 
the bone marrow niche which comprises leukemia cell-preserving endothelial cells 
and mesenchymal stromal cells.12 Drug resistance indeed predisposes chemotherapy 
as a therapeutic rather than curative treatment and contributes to relapse later on.
Refractory and relapsed leukemia cells are reported to upregulate drug efflux trans-
porters and detoxifying enzymes to reduce intracellular drug exposure.10 It has been 
reported that upregulation of the efflux transporter protein, P-glycoprotein, could 
follow repeated treatment with antitumor antibiotics, and thus treatment failure 
and relapse were observed.13 Furthermore, the first-line chemotherapy for AML, 
cytarabine, was found to be less effective in leukemia patients whose cells express 
high levels of SAMHD1 (SAM domain and HD domain-containing protein 1, an 
enzyme for inactivating cytarabine).14 In addition, since several chemotherapeutic 
drugs (e.g. alkylating agents, platinum-based drugs, and tetracycline) induce inter- 
or intra-strand crosslinks and hence DNA damage, cells that have upregulated DNA 
repair mechanism are found to develop resistance.15 In particular, leukemia cells 
with impaired DNA damage response were also reported to resist chemotherapy.16,17
41.2.3 Advances in chemotherapy
Following the Precision Medicine Initiative in combination with personalized 
treatment, there has been a strong tendency to shift the treatment paradigm from 
chemo-based therapy to targeted therapy. Due to the rapid developments in the 
medical researches, a great number of molecular targets have been identified and 
tested for leukemia treatment. Today several targeted therapies e.g. tyrosine kinase 
inhibitors and monoclonal antibodies are available on the clinic. Nevertheless, 
targeted therapy is applicable to a limited population of leukemia patients and 
subjected to quick development of resistance.18,19 It is thus rationale to combine 
the wide applicability of chemotherapy and high specificity of targeted therapy.
Reduce side effect
In clinical practice, prophylactic or palliative medications are adopted to manage 
the side effects caused by chemotherapy, like administration of the antioxidant 
N-acetylcysteine (NAC) for liver protection.20 Pharmacogenetics studies are paving 
the way to elucidate the mechanism underlying organ-specific toxicity caused by 
chemotherapeutic agents. For example, on basis of the causative role of CYP2J2 
in paclitaxel-derived neuropathy, administration of telmisartan (a CYP2J  inhibitor) 
was shown to reduce the severity of neuropathy.21 
During the last decade, researches are more focused on tuning drug  biodistribution 
as a possibility to reduce the off-target effect of chemotherapy. One strategy is to 
design and equip nanocarrier as targeted drug delivery system to leukemia lesions 
and further leukemia cells.22,23 In the case of doxorubicin, adoption of liposomal 
formulation was shown to reduce cardiotoxicity and myelosuppression without 
compromising the clinical outcome.24 Antibody-drug conjugate (ADC) is a com-
plex composed of an antibody targeting surface marker of cancer cell and a small 
cytostatic molecule, thereby featuring the specificity of antibody and toxicity 
of cytostatics. Dozens of ADCs are undergoing clinical trials and two ADCs are 
already approved for leukemia treatment including gemtuzumab ozogamicin and 
inotuzumab ozogamicin.25
Reverse drug resistance
Leukemia cells are persistently evolving to survive from treatments including 
chemotherapy. Several mechanisms of resistance have been revealed by many 
groups as discussed above. Depending on the drug resistance mechanism, cor-
responding inhibitor has been implemented to enhance the sensitivity to chemo-
therapy.26 For instance, in context of chemotherapy resistance caused by impaired 
DNA damage recognition, the small molecule JIB-04 (an inhibitor of multiple 
histone demethylases) could reverse DNA damage recognition in leukemia cells 
and improve the response to cytarabine in vitro and in vivo.16
5Explore novel function of chemotherapy
Immunological cell death (ICD) refers to any kinds of cell death that could initiate 
effective anticancer immune response. The underlying principles include enhance-
ment of the antigenicity (release of neoantigen) and adjuvanticity (activation of 
damage-associated molecular patterns).27 Recognition of ICD induced by chemo-
therapy represents a novel perspective to prolong disease-free survival for cancer 
patients. Rational combination of chemotherapy with immunotherapy, like check-
point inhibitor, could improve the treatment efficacy and increase the survival rate. 
The dose of cytostatics required to induce ICD is significantly lower compared to 
the conventional chemotherapeutic dose in order to avoid excess immunosuppres-
sion.28 Cyclophosphamide, anthracycline and platinum derivatives are among the 
most reported cytostatics to be used as ICD inducers. In AML, translocation of 
calreticulin to the cell surface was implicated in initiation of immune response 
upon chemotherapy.29,30
Develop new chemotherapeutics
Along with optimization of available chemotherapeutics and development of 
novel treatment modalities, there have been continuous efforts to search for new 
chemotherapeutic entities from plants, microorganisms and chemical libraries,31-35 
and synthesize new compounds36. Outstanding examples are the ruthenium com-
plexes37 and selenocompounds (SeCs)38.
1.3 Targeting Oxidative Stress for Leukemia Treatment
1.3.1 Oxidative stress 
Cells mainly utilize oxidative phosphorylation to generate energy, in which each 
oxygen molecule (O2) is eventually converted into harmless water. However, an 
estimation of 2% of O2 consumed receives one electron from the mitochondrial 
electron transport chain per molecule and transforms into superoxide anion  (O2-). 
Superoxide is also produced by nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, xanthine oxidase, and metabolic enzymes. It can be further 
converted to peroxide and peroxynitrite with the help of superoxide dismutase and 
nitric oxide synthase. In proximity with ferrous, superoxide can undergo Fenton 
reaction to yield the highly reactive hydroxyl radicals. Reactive oxygen species 
(ROS) are the collective name describing oxygen-containing radicals as well as 
non-radical species, and the major source of them is mitochondria (Figure 2).39
ROS can modify cellular components and initiate signaling cascades. To regu-
late the biological effects of ROS, cells develop and upregulate the antioxidative 
system comprising both enzymes and non-enzymatic molecules (e.g. glutathione, 
flavonoids, and vitamins). Common antioxidative enzymes include superoxide dis-
6mutase, catalase, thioredoxin, peroxiredoxin, etc. Glutathione (GSH) and NADPH 
are the major reducing equivalents by their own and also function as chaperone 
molecules of many antioxidative enzymes in glutathione and thioredoxin systems. 
The antioxidative system is orchestrated by transcriptional network. One of the 
key transcription factors is nuclear factor erythroid 2-related factor 2 (Nrf2) which 
can upregulate multiple antioxidative molecules.40
Figure 2. Redox regulation in cells
Superoxide anion (O2-) is produced by mitochondrial electron transport chain (Mito-
ETC), endoplasmic reticulum (ER), and NADPH oxidase (NOX). Other forms of ROS, 
like  peroxide, peroxynitrite and hydroxyl radical, could derive from superoxide through 
chemical or enzymatic processes. To maintain redox homeostasis, a range of enzymes 
are available to scavenge different forms of ROS, like superoxide dismutase (SOD), 
catalase and glutathione peroxidase (GPX). The activity of GPX was replenished by 
glutathione reductase (GR) pathway.
Reprinted with permission from American Chemical Society.41
7In healthy cells, the generation and removal of ROS are extremely regulated to 
maintain redox homeostasis; whereas the imbalance of them, referred as oxida-
tive stress, has been noticed in an array of pathological cases including cancer. In 
laboratory test, oxidative stress is usually characterized by the elevation of oxidized 
glutathione (GSSG) in relative to reduced form.
1.3.2 Role of reactive oxygen species in cancer
The role of ROS in cancer can be categorized into two aspects: cancer-promoting 
and cancer-inhibiting (Figure 3). It’s well established that free radicals could 
attack DNA, the damage of which can ultimately lead to mutations and genomic 
instability. This in turn could result in the development of several cancer types. 
In addition, accumulating lines of evidences support that cancer cells could take 
advantage of low to moderate level of ROS as signaling molecules to facilitate 
survival, proliferation, migration, angiogenesis, and etc.42 These observations over-
whelmingly underline the rationale behind reinforcing the antioxidative system, 
like daily supplementation of antioxidants, for cancer prevention.
Figure 3. Generation, regulation and effects of ROS
ROS are byproducts of aerobic metabolism. In normal cells, their level is well controlled 
by endogenous antioxidant. Cancer cells feature high ROS generation as a result of 
 oncogene activation, etc. Moderate level of ROS promotes cancer development and 
 progression via activating many processes like proliferation, genomic instability, etc., while 
the cancer-promoting functions could be abolished by therapeutic antioxidant. Excessive 
ROS however arrest cell cycle and induce cell senescence and death. Therapeutic 
 pro-oxidants can further exacerbate oxidative stress and kill cancer.
Reprinted with permission from Taylor & Francis and adapted.45
8On the other hand, once the level is beyond the tolerance threshold, ROS cause 
irreversible damages to cellular components and jeopardize cell function. In fact, 
this is the mechanism behind the efficacy of radiotherapy for cancer treatment. 
Interestingly, cancer cells in metastasis were reported to suffer from even more 
oxidative stress than the resident counterparts. In consistence, disruption of the 
antioxidative system through inhibition of NADPH synthesis reduced distant 
metastasis of melanoma cells.43 Recently, Wiel et al. have reported that administra-
tion of antioxidants facilitates cancer metastasis by reducing the level of oxidative 
stress.44 The results are of high clinical relevance and public concern but have to 
be confirmed in other investigations.
Due to the fast metabolic cycles, cancer cells have increased ROS generation rate 
and thus higher level of oxidative stress. Oxidative stress in cancer cells is also 
indicated by upregulation of the antioxidative system in compensation to ROS 
generation. In leukemia, ROS are constitutively elevated. Such increment has been 
shown to promote disease progression and drug resistance by inducing genomic 
instability and activing growth signaling and survival pathways.46-48 Persistent 
oxidative stress in leukemia cells predisposes higher vulnerability to further redox 
disruption compared to normal counterparts.49,50 As an alternative to molecular 
targets, oxidative stress might be a promising target that could be exploited for 
leukemia treatment in a selective manner.
1.3.3 Strategies for induction of oxidative stress in leukemia cells
As oxidative stress reflects the imbalance between generation and scavenging 
of ROS, two different strategies are feasible for induction of oxidative stress: 
increasing ROS generation and undermining the antioxidative system (Table 1).
Table 1. Strategies for induction of oxidative stress in leukemia cells
Strategy Method
ROS inducer
Radiotherapy
Chemotherapy
Novel redox-active compound
Nanomedicine
Photodynamic agent
Antioxidative system inhibitor
Inhibitor of antioxidative enzyme 
GSH-depleting agent
GSH synthesis inhibitor
9Radiotherapy is a good example showing that ROS generation could be reliably 
used for cancer treatment.51 In addition, many standard-of-care chemotherapeutic 
agents could directly or indirectly upregulate ROS, like arsenic trioxide, cytarabine, 
vincristine, bortezomib, anthracyclines, histone deacetylase inhibitors, etc.52-57
Many redox-active small molecules are being investigated in preclinical and clini-
cal stages like phenethyl isothiocyanate, β-lapachone and SeCs.58-60 Of notice, the 
well-known antioxidant vitamin C could turn into a pro-oxidant if applied accord-
ing to the proper regimen. In a pioneering clinical trial, high-dose of vitamin C 
demonstrated significant therapeutic efficacy in patients with non-small-cell lung 
cancer and glioblastoma.61 The use of high-dose vitamin C in leukemia patients 
is yet to be explored. Various nanomedicine and photodynamic agents that could 
generate ROS in a controlled manner are also under preclinical development.41,62,63
Heme oxygenase-1 is an indirect antioxidant enzyme and works by synthesis of 
bilirubin for ROS neutralization. Its specific inhibitor protoporphyrine was shown 
to increase ROS level and kill leukemia cells.64 Thioredoxin pathway is vastly 
implicated in redox regulation, and many direct or indirect inhibitors of this path-
way are preclinically proved to be effective against leukemia cells, like auranofin, 
13-hydroxy-15-oxo-zoaptlin and 3-deazaneplanocin A. 65-67
GSH is ubiquitously present in cancer cells at millimolar range. Compounds that 
could quickly deplete GSH have also exhibited strong cytotoxicity to leukemia 
cells.68 GSH is a tripeptide and synthesized from glutamine, cysteine, and alanine 
with the help of several enzymes. Molecules that reduce the availability of  building 
amino acids or inhibit synthase activity could well exacerbate oxidative stress. 
For instance, Cramer et al. has engineered a cysteine-depleting enzyme, cyst(e)
inase, and validated its efficacy in a leukemia mouse model without apparent side 
effects.69 γ-Glutamylcysteine ligase is the rate-limiting enzyme in GSH synthe-
sis. Its specific inhibitor, buthionine sulfoximine, could decrease GSH level and 
significantly suppress leukemia progression stand-alone and in combination with 
other treatments.70,71 Noteworthy, the strategies listed above are indeed not exclu-
sive and many molecules feature multiple functions to exacerbate oxidative stress.
1.4 Redox-Active Selenocompound
1.4.1 Introduction to selenium
In 1817, selenium (Se) was discovered by the Swedish chemist, Jöns Jacob 
Berzelius, following the analysis of an impurity in the sulfuric acid that was pro-
duced at a particular factory in Sweden. The impurity was originally believed to 
be tellurium; however, Berzelius noticed that it was actually a newly discovered 
element. Since the new element resembles tellurium (Tellus is Earth in Latin), 
Berzelius named it selenium after ‘Selene,’ the Greek goddess of the moon.
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The toxicity of Se in farm animals was firstly reported in 1930’s as “Alkali  disease” 
and “Blind Staggers” caused by the excess intake of Se.72,73 Alkali disease was noted 
as severe damage to the hoofs and hair loss; while Blind Staggers was manifested 
by wandering, circling, loss of ability to swallow, and blindness.74 In human being, 
inhalation of Se can cause respiratory membrane irritation, pulmonary edema, 
bronchial inflammation and pneumonia. On the other hand, acute toxicity can be 
manifested as acute respiratory distress syndrome, myocardial infarction, renal 
failure, tachycardia, and neurological features (including tremors, irritability, and 
myalgia).73
During 1950’s, researchers observed that Se is an essential element for bacteria 
and animals. Lack of nutritional Se was later associated with “Keshan Disease” (an 
endemic cardiomyopathy; firstly reported in 1979) and “Kashin-Beck Disease” (a 
chronic, endemic type of osteochondropathy; firstly reported in Siberia during 1849 
and later in China during 1908). Both diseases were reported to occur in low-Se 
areas of China and Russia.75,76 A total of 25 selenoproteins (protein that incorporates 
Se in the form of selenocysteine [SeCys]) are discovered in human,77 while biologi-
cal functions of most selenoproteins are still unclear. Given the redox activity of 
Se, selenoproteins are supposed to have redox-modulating abilities. For instance, 
glutathione peroxidase, thioredoxin reductase, and iodothyronine deiodinase are 
all implicated in redox homeostasis. The benefits of long-term supplementation 
of Se have been associated with redox homeostasis mediated by selenoproteins.78
1.4.2 Selenocompound as chemotherapeutic candidate
SeC refers to the selenium-containing molecule. The rationales behind the pur-
suit of SeCs as chemotherapeutics have two aspects. Firstly, SeCs could produce 
superoxide anion through a chemical process without involvement of particular 
enzymes.79 Secondly, higher vulnerability of cancer cells to further oxidative stress 
compared to healthy cells could confer selective cytotoxicity.49, 80, 81
Diverse SeCs are under preclinical and clinical investigations for cancer chemo-
therapy38, and the list continues to expand. Noteworthy, many synthetic SeCs 
derive from prototypic structures, like selenocyanate, diselenide, isoselenazolone 
as shown in the examples below (Figure 4).
Inorganics
Several inorganic forms have shown anti-leukemic potential including selenite and 
selenium dioxide.82,83 Selenite features the most prominent cytotoxicity and is the 
best studied inorganic SeCs in terms of mechanisms of action and cancer types. 
Epigenetic study reveals that selenite could affect histone function and molecules 
related to oxygen and hypoxia response in the leukemia cell line K562.82 In dif-
ference, another study found that selenite triggers the apoptosis of leukemia stem 
cells through modulation of arachidonic acid metabolism.84
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Selenoamino acids
Selenomethionine (SeMet) and methyl selenocysteine (MeSeCys) are naturally 
existing amino acids in form of monoselenide. Although both are reported to 
inhibit the growth of cancer cell, much higher doses are required in comparison 
to other redox-active SeCs.85,86 This is linked to their poor potency in generation 
of methylselenol (the key active metabolite) due to the deficiency of γ-lyase and 
β-lyase in mammals.87 In accordance, replenishment of specific lyase was shown 
to potentiate the cytotoxicity.88,89
Seleninic acids
Methylseleninic acid (MeSeA) is a precursor of methylselenol and its  cytotoxicity 
has been well documented against lung, prostate and breast cancer.90 It is also 
reported to enhance the efficacy of conventional chemotherapeutics like paclitaxel.91 
In leukemia cells, available data suggest that MeSeA may modulate adhesion and 
migration pathways and interfere with crosstalk with stroma cells.82 Its analogs 
like benzylseleninic acid, phenylseleninic acid have been synthesized while their 
the biological functions remain to be assessed.92
Figure 4. Selenocompounds with chemotherapeutic potential
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Diselenides
Selenocystine (CysSe2) is the oxidized form of selenocysteine. Its anticancer 
efficacy as well as mechanism of action have been explored in vitro and in vivo.93 
CysSe2 could also potentiate the effects of 5-fluouracil and doxorubicin for  cancer 
treatment.94,95 One drawback of CysSe2 is the low solubility in water and also 
organic solvent. To overcome this problem, researchers have encapsulated CysSe2 
into mesoporous silica nanoparticles.96 A plethora of symmetric or  asymmetric 
diselenides with strong anticancer effect have been synthesized.97,98 Among them, 
diphenyl diselenide is another promising candidate due to the efficacy on several 
cancer cell lines.99
Selenocyanates
Organic selenocyanates emerge as important anticancer candidates. The first sele-
nocyanate described for cancer treatment was p-xyleneselenocyanate (p-XSC).100 
It was shown to significantly prevent development of prostate cancer and oral 
carcinoma. Later on, several phenylalkyl selenocyanate analogs were synthesized 
and tested in vitro and in vivo.101-103 Researchers also established structure-activity 
relationship and concluded that longer alkyl chain length corresponds to higher 
tumor-inhibiting effect.101 However, the application of selenocyanates for leukemia 
treatment is limited and the underlying mechanism of action is poorly understood.
Selenium-containing heterocycles
Selenium-containing heterocycles represent a large class of SeCs, and ebselen 
is the first and most studied one in this group. It was originally developed as an 
antioxidant but later recognized as a pro-oxidant while used at higher concentra-
tion.104 Several studies have proven its ability to treatment solid tumor,105,106 and 
recently Laverdière et al have demonstrated that ebselen also targets leukemia 
stem cells.107 However, ebselen is poorly soluble in water and alternative formula-
tion is required for therapeutic usage. Immerse efforts have been made to develop 
new heterocyclic SeCs using ebselen as a prototype.108-110 For instance, ethaselen 
demonstrated remarkable efficacy against leukemia as well as many other types 
of cancer and has entered phase II clinical trial.111,112
1.4.3 Cellular uptake
SeCs exert selective toxicity on cancer cells in relative to normal cells. In addi-
tion to the differential basal ROS level between cancer and normal cells, another 
underlying mechanism was thought to be selective uptake. Early studies have 
shown that radiolabeled SeCs (75Se-selenite and 75Se-SeMet) have preferable 
distribution into the tumor in comparison to healthy tissues and could be used for 
13
tumor diagnostics.113,114 After intravenous administration of radiolabeled selenite, 
a large percentage of selenium was detected in red blood cell.115 In addition, it 
was reported that presence of reducing agents, either cysteine116 or glutathione117, 
could facilitate uptake of selenite into the cancer cell, implying that reduced forms 
of selenite are preferable. However, assessment of SeCs uptake is based on quan-
tification of total elemental Se intracellularly post exposure; therefore the exact 
uptaken form of Se is unknown. So far, only a few reports have suggested that 
anion transporters play a role in mediating the uptake of selenite and SeMet.114,115 
For the majority of SeCs, the uptake mechanism is not fully understood.
1.4.4 Mechanism of action
In the presence of GSH, SeC could transform into selenol or selenolate (the 
deprotonated form of selenol) which then reacts with molecular oxygen and yields 
superoxide anion. Along with other downstream ROS derived from superoxide, 
cellular ROS level is eventually elevated. Multiple intracellular molecules  including 
proteins and nucleic acids are potential targets of ROS, resulting into oxidative 
damages (Figure 5).38 Low degree of damage could be partially or completely 
offset by the endogenous antioxidative system and exogenous antioxidants. In 
addition, emerging evidences suggest that the activity of SeCs might be carried 
out through direct protein modification by redox-active metabolites, for example 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells).118
Figure 5. Mechanism behind the cytotoxicity of selenocompounds
Redox-active SeC could transform into the active selenolate intermediate (RSe−) which 
then transfers one electron to oxygen molecule, yielding superoxide. In proximity with 
other enzymes or molecules, superoxide can generate downstream forms of ROS for 
inducing oxidative damages to proteins and DNA. This redox cycle also produces selenyl 
radical (RSe•) which can in turn refuel selenolate.
Reprinted with permission from Elsevier and adapted.119 
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Mechanisms underlying cell death caused by oxidative damage are diverse.61 
Different modes of cell death like apoptosis, necrosis, autophagy, and necropto-
sis might take place alone or in parallel, which are structure-, concentration and 
time-dependent.120 Chemoresistance due to the loss-of-function of certain com-
ponents in cell death pathways is one of the major hurdles for current treatments. 
However, this hurdle might be less concerned with for SeCs which could prime 
diverse cell death machinery.
1.4.5 Speciation and quantification
The biological activities vary between different SeCs and their metabolites. To 
improve the use of SeCs in chemotherapy, it is a prerequisite to quantify the dif-
ferent forms of Se, rather than total Se as an element.121 Substantial efforts are 
being dedicated to speciation and quantification of SeCs as summarized below 
(Table 2).122,123
Table 2. Features of different selenium speciation and quantification strategies
Strategy Chromatography X-ray absorption 
spectroscopy
Chemical probe
Advantage • High specificity and 
sensitivity
• Wide applicability
• High availability in 
instrument
• Minimal sample 
preparation
• Wide applicability
• Minimal sample 
preparation
• Utility in cells and 
 animals non-invasively
• High availability in 
instrument
Limitation • Complex and 
 bias-prone  sample 
preparation
• Need prior knowledge 
for  specie identification
• Semi-quantitative
• Low availability in 
instrument
• Complex data 
analysis
• Qualitative
• Only detect total selenol
Chromatography
Chromatography is a traditional separation technique based on varying partition 
coefficient of compounds between mobile and stationary phases. The most adopted 
separation techniques are gas chromatography (GC) and liquid chromatography 
(LC).124 GC is useful for separation of volatile species, like methylselenol, dime-
thyl selenide and dimethyl diselenide; while LC has much more general utility.
Before separation, sample pretreatment is required to enrich the species of interest 
and remove irrelevant components (like lipids and proteins).123,125 The choice of 
pretreatment method is based on matrix type, species of interest and instrumental 
requirement. Many Se species are known to be unstable (i.e. SeMet and SeCys), 
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thus species interconversion/loss during pretreatment is expected. In additional, 
extraction efficiency might vary for different species, which would introduce great 
bias to data interpretation. To minimize variation during pretreatment, a usual way 
is to apply internal standard that has similar physiochemical property as the  species 
of interest. However, this is hampered by shortage of internal standard and poor 
knowledge of Se species in complex matrix.
Identification of species follows samples pretreatment and separation. In the 
simplest situation, this could be achieved by comparing the retention time of the 
sample to that of reference. Alternatively, mass spectrometry (MS) is a powerful 
tool in identification of new Se species. In fact, tandem GC/LC-MS is the major 
methodology in the field of Se speciation and quantification. Furthermore, there 
are other atomic detectors which could enable extremely high sensitivity, e.g. 
inductively coupled plasma atomic emission spectroscopy and microwave induced 
plasma atomic emission spectrometry.126 
X-ray absorption spectroscopy
Although chromatography remains the mainstream method in Se speciation, it holds 
several intrinsic limitations. Synchrotron X-ray is a type of extremely bright light 
of high energy. The electrons of Se could be readily excited by the high energy 
from X-ray and generate spectrometric properties that are distinguishable from 
other elements. The spectrometric feature is also dependent on the type of bond 
that Se forms.127 During analysis with X-ray absorption spectroscopy (XAS), 
sample preparation procedure is rather facile. In this regard, the possibility of 
species interconversion is minimized, making synchrotron X-ray a promising tool 
for Se speciation. Prince RC et al. carried out one of the pioneering endeavors by 
acquiring distinct absorption spectrograms of several selenoamino acids.128 After 
obtaining the spectra of unknown samples and pre-selected reference materials, 
linear regression analysis can be carried out to perform semi-quantification of Se 
species. Using this strategy, Harris HH et al. have recently succeeded to illustrate 
the dynamic metabolic profile of selenite in human lung cancer cells.129
Chemical probe
Selenols are the active metabolites of SeCs and also critical sites for many seleno-
proteins. Visualization of selenols has received tremendous interests in the last 
decades with a plethora of fluorescent selenol probes been reported so far. In 
principle, all probes take advantage of the exceptional reactivity of selenol.130-133 
Those probes have been tested in cell cultures or living animals like zebrafish and 
mouse, which contributed to a better understanding of the fate of selenols in vivo. 
One major limitation of those chemical probes is that none of them are able to 
distinguish different selenol forms.
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1.4.6 Metabolism and pharmacokinetics
Among the diverse SeCs investigated for cancer chemotherapy, only a few were 
particularly studied in terms of metabolism and pharmacokinetics. The  metabolism 
of selenite in the lung cancer cells has been studied using XAS semi-quantitatively.129 
With a dedicated chromatography method, Terlinden et al found that after oral 
administration ebselen quickly became undetectable in human plasma and two 
major metabolites were identified.134 El-Bayoumy’s group also used  chromatography 
method to study the metabolism of orally administered p-XSC and identified tetra-
selenocyclophane as a major metabolite in mouse feces.135
In general, the metabolic pathway and pharmacokinetics of SeCs are poorly inves-
tigated, which most probably is due to the fact that most preclinical studies and 
clinical trials utilize the quantification methods that only detect the total amount of 
Se as an element.136,137 More efforts are warranted to depict how SeCs are metabo-
lized in vivo as an important part of translational endeavors.
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2 AIMS
Even though current treatment strategies have greatly improved the survival of 
patients suffering from hematological malignancies, complete and long-term remis-
sion of leukemia is still far from reality, demanding further endeavors to improve 
the clinical outcome. Selenocompounds have exhibited therapeutic potential in 
the treatment of solid tumors through induction of oxidative stress; however, their 
roles in leukemia treatment are poorly explored.
The general aim of the present thesis was to explore the anti-leukemic activity of 
selenocompounds. Our specific aims were:
• To study the anti-leukemic efficacy of selenocompounds in vitro
• To selectively quantify selenocompounds in plasma
• To investigate the mechanism of cellular uptake of selenocompounds 
• To explore the pharmacokinetics and evaluate the anti-leukemic effect of 
selenocompounds in vivo
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3 MATERIALS AND METHODS
3.1 Reagent
MeSeA (Catalog No. 541281), CysSe2 (Catalog No. 545996), N-ethylmaleimide 
(NEM; Catalog No. 389412), tris(2-carboxyethyl)phosphine (TCEP; Catalog No. 
75259), bovine serum albumin (BSA; Catalog No. A7030), and human serum 
albumin (HSA; Cat. No. A1653) were purchased from Sigma-Aldrich. Ebselen 
(Catalog No. ALX-270-097) and p-XSC (Catalog No. ab142600) were bought 
from Enzo Life Sciences and Abcam, respectively.
Different solvents were applied to prepare the stock solutions for the SeCs  depending 
on particular use. For cell and animal experiments, CysSe2 and MeSeA were dis-
solved in DPBS (0.7-1 mg/mL) and the pH thereof was always adjusted till around 
7.4; while the solvent was H2O in speciation & quantification section. For Ebselen 
and p-XSC, the solvents used were DMSO (for cell experiment; 1.5 mg/mL), 
acetonitrile (for speciation & quantification section), and DMSO/Cremophor EL 
(w/v of 1:1; for animal experiment; 5 mg/mL).
3.2 Cell Experiment
3.2.1 Cell culture condition
C1498 (ATCC; Catalog No. TIB-49) and C1498-luc (PerkinElmer, prepared 
upon request) were cultured in DMEM (ThermoFisher; Catalog No. 41966) 
supplemented with 10% fetal bovine serum (FBS; ThermoFisher; Catalog No. 
41966) and penicillin (100 U/mL)-streptomycin (0.1 mg/ml) (Sigma-Aldrich; 
Catalog No. P4333). HL60 (DSMZ; Catalog No. ACC3), KG-1a (DSMZ; Catalog 
No. ACC421) and K562 (ATCC; Catalog No. CCL243) cells were cultured in 
RPMI1640 (ThermoFisher; Catalog No. 41966) supplemented with 10% FBS 
and 1X penicillin-streptomycin. HUVEC (kindly provided by Eva Wärdell) cells 
were grown in MV2 medium (PromoCell; Catalog No. C22022). The medium 
with appropriate full supplements was hereafter referred as complete medium.
All cells were maintained at 37 °C with 5% CO2 and the viability was assayed by 
trypan blue routinely. Only cells under exponential growth phase and with trypan 
blue positivity ≤ 5% were used.
3.2.2 Determination of cell viability
Leukemia cells (1×105 cells/mL; 0.1 mL/well) were treated with SeC in 96-well 
plates for different periods. For HUVEC cells, a total of 5×103 cells were seeded 
24 hr before treatment. Cell viability was determined using either CellTiter-Glo 
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kit (Promega; Catalog No. G7571; 100 µL/well) or WST-1 kit (Sigma-Aldrich; 
Catalog No. 11644807001; 10 µL/well plus 2 hr incubation). Signals were quanti-
fied using the microplate reader (SpectraMax i3x). In combination treatment p-XSC 
was added 2 hr or 1 hr later after NAC (Sigma-Aldrich; Catalog No. A7250) or 
Z-VAD-FMK (Enzo; Catalog No. ALX-260-020-M005), respectively. In some 
cases, treatment was performed in medium without FBS and without/with BSA.
3.2.3 Determination of oxidative stress
Two different assays were used to determine oxidative stress in cells. In the first 
assay, C1498-luc cells (1×106 cells/mL) were treated with 20 µM of the fluores cent 
ROS probe, DCFDA (Abcam; Catalog No. ab113851) for 30 min. The DCFDA-
loaded cells (1×105 cells/mL) were then treated with p-XSC for 4 hr. In combina-
tion treatment with NAC, cells were successively treated with NAC (5 mM; 2 hr), 
DCFDA and p-XSC with rinsing step between each treatment. Cellular fluores-
cence images were captured using microscope (Olympus IX81; cellSens software 
1.16) and the signals were also quantified using microplate reader. Phenol red-
free DMEM (ThermoFisher; Catalog No. 31053) was used to avoid interference.
The second assay refers to measurement of glutathione level. Briefly, C1498-luc 
cells (1×106 cells/mL; 5 mL) were treated with p-XSC and harvested at different 
time points. The cells were lysed using 80 µL of hydrochloric acid (10 mM) and 
glutathione level in the lysate was determined using a colorimetric kit following 
the manufacturer’s instructions (Sigma-Aldrich; Catalog No. 38185).
3.2.4 Determination of intracellular selenium element
C1498 cells (2 ×106 cells/mL; 4 mL) were treated with SeC and pelleted 30 min 
later. The pellet was rinsed and lysed with 0.4 mL lysing buffer (Promega, Catalog 
No. E153A). The supernatant afforded through centrifugation (1×104 g, 10 min) 
was diluted with H2O till 4 mL and subjected to Se measurement on inductively 
coupled plasma atomic emission spectrometer (iCAP 6500, ThermoFisher). The 
standard curve was acquired using selenium reference solution (Sigma-Aldrich; 
Catalog No. 50002).
3.2.5 Transmission electron microscopy
C1498 cells (1×106 cells/mL; 1 mL) were treated with p-XSC and harvested at 
different time points. The cells were immediately fixed in 2.5% glutaraldehyde 
overnight and immersed in 2% osmium tetroxide for 2 hr. After dehydration and 
embedding, ultrathin sections (~ 50 nm) were cut and examined using microscope 
(Tecnai 12 Spirit BioTwin; FEI Company) at 100 kV.
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3.2.6 Western blot
C1498-luc cells (1×106 cells/mL; 20 mL) were treated with p-XSC and harvested 
at different time points. The cell pellet was lysed using RIPA buffer (CST; Catalog 
No. 9806) supplemented with proteinase/phosphatase inhibitor (CST; Catalog 
No. 5872) and concentration of total protein thereof was quantified using BCA 
kit (ThermoFisher; Catalog No. 23227). Around 15-20 µg of protein were loaded 
on 10% precast TGX polyacrylamide gels (Bio-Rad; Catalog No. 4561036) and 
transferred onto a PVDF membrane (GE healthcare; Catalog No. 10600023). The 
membranes were blocked using 5% non-fat milk (CST; Catalog No. 9999) and 
incubated with primary antibodies overnight at 4 °C. The primary antibodies were 
against Actin (Sigma-Aldrich; Catalog No. 2066, 1: 400) and AIF (CST; Catalog 
No. 4642, 1: 500). Protein band was stained with fluorescent second antibody 
at room temperature for 45 min (anti-mouse or rabbit IRDye 680RD/800CW, 1: 
10,000; Li-cor) and captured (Odyssey 9120, Li-cor).
3.2.7 Flow cytometry
C1498-luc cells (1×105 cells/mL; 2 mL) were treated with p-XSC and harvested 
at different time points. The cells were stained with 10 µL of PE-Annexin V and 
10 µL of 7-AAD solution (BD; Catalog No. 556547) for 15 min at room tem-
perature. Data were acquired on 1×104 cells and analyzed using flow cytometry 
(BD FACSArray).
3.3 Speciation and Quantification
3.3.1 Synthesis of selenol derivative
To synthesize the selenol derivative (SeC-NEM), SeC solution was mixed with 
NEM and then TCEP for 30 min at room temperature. Detailed loading amount of 
the materials was available in our publications.138,139 The derivative was purified 
using preparative liquid chromatography and validated using 1H-NMR (nuclear 
magnetic resonance, Bruker DRX-400, 400 MHz) and ESI-MS (electrospray 
ionization-mass spectrometry, Thermo TSQ Quantum Ultra).
3.3.2 Quantification of selenocompound
Two different strategies were utilized to extract SeC for subsequent quantifica-
tion: (1) direct deproteinization; (2) RECID (REductive Cleavage and Instance 
Derivatization). During direct deproteinization, 50 µL of acetonitrile was mixed 
with 20 µL of matrix. In RECID, NEM (10 µL, 0.4 M in dimethylacetamide) and 
TCEP (5 µL, 0.2 M in H2O) were successively added into 15 µL of matrix, followed 
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by vortex for 30 sec and reaction for 10 min at room temperature. The mixture was 
centrifuged (3×104 g, 10 min) and 2 µL of the supernatant afforded was injected 
into the LC-MS analyzer (Thermo TSQ Quantum Ultra). Detailed LC conditions 
and MS parameters were available in our publications.138,139
3.3.3 Determination of albumin binding degree
SeC solution (40 µg/mL; 200 µL) was mixed with equal volume of H2O (control) 
or 5% BSA. The mixture was added to ultrafiltration tube (cut-off 10 kDa; Sigma-
Aldrich; Catalog No. 13239E) and centrifuged (2×103 g and 5 min). SeC in the 
ultra-filtrate was measured directly using LC-MS. Albumin binding degree was 
calculated as the percentage of SeC peak area in BSA in relative to that in control.
3.3.4 X-ray absorption spectroscopy
The conjugate between selenocompound and albumin (SeC-albumin) was firstly 
prepared. Briefly, SeC solution was mixed with albumin and kept at room tem-
perature for 30 min. The loading amount of the materials was detailed in our pub-
lications.138,139 The conjugate was obtained after purification using gel permeation 
chromatography (Superdex 200 Increase 10/300 GL column) and lyophilization. 
SeC-HP or SeC-FBS samples were prepared through mixing SeC and human 
plasma or FBS, respectively, and subsequent lyophilization.
The samples including SeC, SeC-albumin, SeC-FBS and SeC-HP were formulated 
into small pellets (diameter 5 mm). Se K-edge XAS measurements were performed 
in QEXAFS mode using a Si(311) double-crystal monochromator in CLAESS 
beamline at ALBA synchrotron light facility (Cerdanyola del Valles, Spain). All 
measurements were performed at liquid N2 temperature to avoid radiation damage. 
Data were analyzed using Demeter software package (version 0.9.26).
3.4 Animal Experiment
3.4.1 Pharmacokinetic study
Animal experiments were approved by the Stockholm Southern Ethical Committee 
(ethical permit no. ID 1031). SeCs were intravenously or intraperitoneally injected 
into C57BL/6 albino mouse (CysSe2 and MeSeA: 5 mg/kg; ebselen and p-XSC: 
2 mg/kg). Blood samples were collected at different time points post administra-
tion and SeCs concentration in plasma was analyzed using RECID as described 
above. The concentration-time curves were modeled using WinNonLin software 
(version 2.0) to calculate pharmacokinetic parameters.
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3.4.2 Leukemia mouse model
The leukemia mouse model was established through intravenous inoculation 
of C1498-luc cells (1×106 cells in 100 µL DPBS) into C57BL/6 albino mouse. 
Disease progression was longitudinally monitored using in vivo imaging system 
(IVIS® Spectrum; PerkinElmer) after i.p. injection of D-luciferin (15 mg/mL in 
DPBS; PerkinElmer). p-XSC treatment (daily i.v.; 2 mg/kg) was initialized 11 days 
post cell inoculation and continued for 5 days. All mice were sacrificed 22 days 
after cell inoculation; bone marrow from both femurs was immediately flushed. 
Bioluminescence signal in bone marrow samples was measured by mixing 100 µL 
D-luciferin (3 mg/mL) with 100 µL bone marrow flush and captured using IVIS. 
Data were analyzed using Living Image software (version 4.5.5).
3.5 Statistics
Results were shown as mean ± standard deviation if appropriate. Two-sided Mann-
Whitney test was used to compare the means between two groups. p ≤ 0.05 was 
considered statistically significant.
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4 RESULTS 
4.1 Selenocompounds Have Prominent Anti-Leukemic 
Effect in Vitro
Most SeCs currently under investigation derive from structural modification 
of prototypic compounds and have common structures such as monoselenide, 
seleno cyanate, seleninic acid, diselenide and isoselenazolone. Therefore, to gain 
a better understanding of their anti-leukemic activity, we selected six candidates 
representing different classes of SeCs (Figure 6). All the SeCs selected have shown 
anti-cancer activity according to previous reports.38
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Figure 6. Chemical structures of selenocompounds used in this thesis
Prototypic structures were highlighted in red.
4.1.1 p-Xyleneselenocyanate has superior toxicity on 
leukemia cells
C1498-luc is an aggressive murine AML cell line and was utilized as the primary 
model for assessing the anti-leukemic efficacy of SeCs. Among the six SeCs 
studied, p-XSC displayed the highest cytotoxicity against C1498-luc cells with 
half-inhibitory concentration (IC50) of 4.8 µM after 24 hr treatment (Figure 7A) 
and thus was used in further investigations. To confirm a general anti-leukemic 
efficacy of p-XSC and increase clinical relevance, we characterized the efficacy of 
p-XSC on several leukemia cell lines of human origin: K562 (chronic myelogenous 
leukemia), HL-60 (acute promyelocytic leukemia) and KG-1a (acute myelogenous 
leukemia). p-XSC was similarly effective in killing human leukemia cells with 
sharp dose-effect profiles (IC50 ranged 4.9-11.3 µM; Figure 7B). In comparison, 
higher concentrations of p-XSC were required to kill the non-cancerous fibroblasts 
and endothelial cells (IC50 over 15 µM; data not shown). These findings suggest 
the selective cytotoxicity of p-XSC against leukemia over non-cancerous cells.
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4.1.2 p-Xyleneselenocyanate induces oxidative stress of 
 leukemia cells 
To understand the underlying mechanism of action, we exploited a cell-permeable 
probe, DCF-DA, which fluoresces upon exposure to reactive oxygen species (ROS) 
in C1498-luc cells. Compared to the vehicle control, much stronger fluorescence 
signals were detected in p-XSC-treated cells (Figure 8A). N-acetylcysteine (NAC), 
a commonly used antioxidant, significantly reduced cellular ROS (Figure 8B). In 
accordance, the cytotoxicity of p-XSC was completely abrogated by NAC, while 
NAC itself has no effect on cell viability at the dose applied (Figure 8C). These 
findings imply that the cytotoxicity of p-XSC on leukemia cells is mediated by 
induction of ROS generation.
Alteration of intracellular glutathione is one of the best markers during oxidative 
stress and was also examined in C1498-luc cells (Figure 8D). Since higher cell 
mass is required for glutathione measurement, p-XSC concentration was escalated 
to the range of 5-25 µM to achieve the same phenotype. In line with the absence of 
cytotoxicity for 5 µM of p-XSC (data not shown), total glutathione level returned 
to basal level in spite of an initial decrease by 1 hr. Glutathione variation in case 
of 15 µM exhibited a clear time-dependence as demonstrated by the steep decline 
during the period of 2-3 hr. Increasing p-XSC concentration till 25 µM led to a fast 
exhaustion of glutathione. Overall, the pattern in glutathione depletion corroborates 
the findings from cytotoxicity as well as mechanistic studies above.
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Figure 7. Cytotoxicity of selenocompounds on leukemia cell lines
(A) C1498-luc cells were treated with different SeCs for 24 hr and cell viability was 
determined using CellTiter-Glo kit. (B) KG-1a, HL60 and K562 cells were treated with 
p-XSC for 24 hr. Cell viability was determined using WST-1 kit. Cell concentrations were 
all 1×105 cells/mL. N = 3.
Reprinted with permission from Springer Nature.
27
4.1.3 Mitochondrion is the primary target of p-xyelenselenocyanate
To reveal specific organelle affected by p-XSC, we investigated ultrastructural 
alteration using transmission electron microscopy (TEM; Figure 9A) in C1498-luc 
cells. Mitochondria were filled up with big vacuoles after treatment with 25 µM 
of p-XSC for 30 min. In fact, the phenotype was already present with less severity 
at an early time point (5 min). No major ultrastructural change was observed at 
5 µM which was not toxic (Figure 8D). Next we used Annexin V/7-AAD stain-
ing to reveal whether the cell death is in mode of apoptosis. Again, we found 
that  apoptosis did not initiate until 2 hr post treatment (8 µM of p-XSC) and all 
cells became apoptotic in the next hour, confirming critical time-dependence of 
the cytotoxicity (Figure 9B). Furthermore, noticeable upregulation of apoptosis-
inducing factor (AIF) was detected upon p-XSC treatment (25 µM; Figure 9C). In 
accordance with the knowledge that AIF acts through caspase-independent path-
way, the pan-caspase inhibitor, Z-VAD-FMK, did not compromise the cytotoxicity 
of p-XSC at all (Figure 9D). In total, the cytotoxicity of p-XSC was pertinent on 
massive mitochondria damage and apoptotic cell death.
Figure 8. Implication of oxidative stress in the cytotoxicity of p-xyleneselenocyanate
(A) C1498-luc cells (1×105 cells/mL) were treated with 8 µM of p-XSC or vehicle for 4 hr. 
Intracellular ROS was stained using a green fluorescent dye DCF-DA. Representative 
microscope pictures were shown. The scale bar applies to all pictures. (B) C1498-luc 
cells (1×105 cells/mL) were treated with 5 mM of NAC for 2 hr and then with p-XSC for 4 
hr. Intracellular ROS were quantified. N = 3. (C) C1498-luc cells (1×105 cells/mL) were 
treated with 5 mM of NAC for 2 hr and then with p-XSC for 24 hr. Cell viability were 
determined using WST-1 kit. N = 6. (D) C1498-luc cells (1×106 cells/mL) were treated 
with p-XSC and intracellular glutathione level was determined. N=3.
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4.2 Quantification of Selenocompounds in Plasma
Results above highlighted that the activity of SeCs is determined by compound 
type, concentration as well as treatment duration. To ensure adequate drug expo-
sure, one practical measure is to optimize treatment regimen on basis of the 
pharmacokinetic properties. However, there is no citable report on SeCs to the 
best of our knowledge, motivating us to establish a quantification method that is 
amenable to plasma setting.
Figure 9. Cellular mechanism underlying the cytotoxicity of p-xyleneselenocyanate
(A) C1498-luc cells (1×106 cells/mL) were treated with p-XSC and the ultrastructure was 
imaged using transmission electron microscope. The scale bar applies to all pictures. 
(B) C1498-luc cells (1×105 cells/mL) were treated with 8 µM of p-XSC and then stained 
for apoptosis analysis. Representative scatter plots from flow cytometry were shown. 
(C) C1498-luc cells (1×106 cells/mL) were treated with 25 µM of p-XSC. Protein level of 
apoptosis-inducing factor (AIF) in the whole cell lysate was determined using western blot. 
(D) C1498-luc cells (1×105 cells/mL) were treated with Z-VAD-FMK (50 µM) for 1 hr and 
then together with p-XSC for 24 hr. Cell viability was determined using WST-1 kit. N = 6.
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4.2.1 Direct deproteinization fails to extract selenocompounds
Deproteinization is the most common method to extract drugs in free and non-
covalently bound forms from plasma prior to analysis. SeCs were firstly extracted 
from plasma through direct deproteinization and their levels were measured using 
LC-MS. Quantification of CysSe2 and MeSeA was however prohibited due to strong 
matrix effect on compound ionization (data not shown) that is indeed commonly 
present in the interface of LC and ESI-MS. Since albumin is the major plasma 
protein, we used 5% BSA as the matrix instead of plasma to examine the extrac-
tion efficiency. Interestingly, MeSeCys and SeMet were easily extracted with 
efficiency over 95%; whereas the extraction efficiencies for the other four SeCs 
were as low as 0-28% (Figure 10A). In consistence, low degrees of albumin bind-
ing (< 3%) were observed for MeSeCys and SeMet; while the rest demonstrated 
high albumin binding ability (Figure 10B).
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Figure 10. Extraction of selenocompounds from albumin solution
SeC was mixed with 5% BSA solution and extracted using direct deproteinization (A) or 
ultrafiltration (B) strategy. Final concentration of SeC in matrix was 20 µg/mL. SeC was 
quantified using LC-MS. N.D. refers to not detected. N = 3.
Reprinted with permission from Springer Nature.
4.2.2 Selenocompounds bind to albumin through selenium-
sulfur bond
In order to confirm the binding type, SeCs were firstly made to react with serum 
albumin from bovine (BSA) or human (HSA). The selenocompound-albumin conju-
gate (SeC-albumin) was purified and analyzed using XAS. Both the X-ray absorp-
tion near edge spectrum (XANES; Figure 11A) and extended X-ray absorption fine 
structure (EXAFS; Figure 11B) of SeC-albumin markedly differed from that of 
the corresponding SeC, indicating changes in the coordination of Se. Noteworthy, 
the EXAFS signals were similar for the eight SeC-albumin samples (Figure 11B). 
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Further modeling of the pseudo-radial distribution function of EXAFS supported 
that Se coordinated with sulfur (S; Table 3). Moreover, linear combination fitting 
using the reference spectra of SeC-HSA (the conjugate between selenocompound 
and human serum albumin) and SeC was carried out to assess the amount of each 
form in the mixture of SeC and human plasma (SeC-HP). Results showed that 
SeC-HSA was always a major constituent in SeC-HP (Figure 11C).
Table 3. Coordination of selenium in the conjugate between selenocompound 
and human serum albumin
The analysis was based on modelling of the EXAFS signal. The k-range was 
 2.6-13.3 Å-1 (exception: 2.6-10.1 Å-1 for MeSeA-HSA). The amplitude reduction 
 factor (S02) was fixed to 0.85. 
SeC-HSA Atom Number E0 (eV) R (Å) σ2 (Å2) R-factor
CysSe-HSA
C 1
6.7
2.016 0.003
0.047
S 1 2.191 0.001
MeSeA-HSA
O 1
5.8
1.745 0.030
0.004
S 1 2.178 0.002
Ebselen-HSA
C 1
7.0
1.957 0.002
0.024
S 1 2.205 0.002
p-XSC-HSA
C 1
6.9
1.972 0.009
0.036
S 1 2.190 0.003
Reprinted with permission from Springer Nature.
Figure 11. X-ray absorption spectroscopy measurement
(A-B) X-ray absorption near edge spectrum and extended X-ray absorption fine structure 
of SeC (black), SeC-HSA (red), and SeC-BSA (green). (C) Amount of different forms of 
SeC in SeC-HP estimated from linear combination fitting. Total concentration of SeC in 
SeC-HP was 20 µg/mL.
Reprinted with permission from MDPI as well as Springer Nature, and adapted.
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To further understand how Se-S bond forms, we used a thiol-reactive agent, NEM, 
to eliminate the effect of albumin thiol. Compared to pristine albumin, higher extrac-
tion efficiencies of SeCs were obtained after blocking albumin thiols (Figure 12A). 
Selenol is the major active metabolite and its abundance has been positively corre-
lated with cytotoxicity. In order to know whether generation of selenol is implicated, 
we correlated cytotoxicity (Figure 7A) and albumin binding ability (Figure 10B; 
Figure 11C) of SeCs. Interestingly, only the four compounds with prominent albu-
min binding (i.e. CysSe2, MeSeA, ebselen and p-XSC) were cytotoxic. Moreover, a 
negative correlation was found between IC50 and albumin binding degree acquired 
from both XAS and LC-MS measurements (Figure 12B), suggesting a causative 
role of selenols. Given the vulnerability of Se-S bond to reduction and high reactiv-
ity of selenol, we used TCEP/NEM to take a snapshot of the selenol structure. The 
speculated selenol derivative of SeC (SeC-NEM; Figure 12C) was synthesized and 
validated using ESI-MS and 1H-NMR (data not shown). On the basis of the results 
above, we reasoned that cytotoxic SeCs could transform into selenols which react 
with albumin thiol through Se-S bond.
Figure 12. Role of selenol and thiol in albumin binding
(A) Extraction efficiency of SeC from 5% BSA and NEM-BSA (BSA treated with NEM; 5%) 
through deproteinization in relative to H2O. SeC concentration was 20 µg/mL. N.D. refers 
to not detected. N = 3. (B) Linear regression between IC50 and albumin binding degree of 
SeCs. IC50 was calculated from Figure 7A; albumin binding degree was retrieved from LC-MS 
(Figure 10B) and XAS (Figure 11C) measurements. The goodness of fitting is shown as r2. 
(C) Structure of the selenol derivative (SeC-NEM). The selenol inter mediate is labeled as blue.
Reprinted with permission from Springer Nature.
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4.2.3 Extraction of total selenocompounds using RECID
In order to quantify the free and albumin-bound SeCs in plasma, we established the 
REductive Cleavage and Instant Derivatization method (RECID) which contains 
three consecutive steps: (1) generation of selenol intermediate by TCEP; (2) deri-
vatization of the selenol intermediate by NEM; (3) extraction of the derivative by 
deproteinization (Figure 13A).
Figure 13. Quantification of selenocompounds in plasma using RECID
(A) Scheme of Se-S binding model and the reductive cleavage and instant derivatization 
method (RECID). (B) Representative chromatograms of SeCs in human plasma using 
RECID.
Reprinted with permission from Springer Nature as well as American Chemical Society, and adapted.
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The reaction time, amount of TCEP/NEM, as well as the order in addition of 
TCEP/NEM was optimized. RECID was also methodologically validated in terms 
of  accuracy, precision, recovery and stability (data not shown). In general, sample 
preparation could be finished within 30 min and running time was less than 20 min. 
Using the optimized RECID and LC-MS conditions, we managed to detect total 
SeCs of high specificity in plasma (Figure 13B).
4.3 Albumin Sequesters Selenocompounds and Limits 
Their Efficacy
Given the covalent binding between SeCs and BSA, albumin binding was assumed 
to prevail in cell culture medium that is universally supplemented with fetal bovine 
serum (FBS; 10% in most cases). We are thus interested in elucidating the extent as 
well as the way in which albumin binding affect the activity of SeCs.
4.3.1 Selenocompounds form conjugates with serum albumin
Firstly of all, we investigated the transformation of SeCs at a concentration of notable 
cytotoxicity. SeCs were mixed with FBS (SeC-FBS) rather than complete medium 
to ease sample preparation and then subjected to XAS measurement. Similarly, we 
found that Se coordinated with S in SeC-FBS samples (Table 4). Moreover, EXAFS 
fitting indicated that 40% of CysSe2 and ebselen added in FBS formed Se-S bond; 
while all p-XSC and MeSeA were transformed.
Table 4. Coordination of selenium in the mixture of selenocompound and fetal 
bovine serum
The analysis was based on modelling of the EXAFS signal. The k-range was  2.5-13.0 Å-1. 
The amplitude reduction factor (S02) was fixed to 0.85.
SeC-FBS Atom Number E0 (eV) R (Å) σ2 (Å2) R-factor
CysSe-FBS
(300 µM)
C 1
4.8
2.003 0.006
0.022S 0.4 2.139 0.004
Se 0.6 2.322 0.001
MeSeA-FBS
(200 µM)
O 1
4.0
1.682 0.003
0.008C 1 2.359 0.004
S 1 2.203 0.008
Ebselen-FBS
(300 µM)
C 1
5.0
1.920 0.004
0.016S 0.4 2.191 0.002
Se 0.6 2.355 0.004
p-XSC-FBS
(100 µM)
C 1
6.5
2.009 0.003
0.017
S 1 2.185 0.002
Reprinted with permission from MDPI.
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Besides albumin thiols, small molecule thiols like GSH and Cys are present 
in fresh and conditioned cell culture medium. In order to clarify whether these 
small molecule thiols could participate in transforming SeCs, we characterized 
its conjugate with SeCs (SeC-SM) if present. p-XSC had high reactivity to GSH 
and Cys (the conjugates were collectively abbreviated as p-XSC-SM)133 and was 
chosen for this purpose.
Free p-XSC in complete medium was extracted using direct deproteinization and 
quantified. It was undetectable when p-XSC concentration was below 12 µM; and 
addition of extra 1% BSA further depleted free p-XSC (Figure 14A). To facilitate 
the characterization of p-XSC-SM, p-XSC concentration was fixed to 10 µM 
where no free p-XSC was present. The macromolecular conjugate p-XSC-BSA 
(the conjugate between p-XSC and BSA) was then filtered using a centrifugation 
tube (molecular weight cut-off 10 kDa; Figure 14B). The filtrate was analyzed in 
terms of p-XSC-SM amount, cellular uptake as well as toxicity profiles. Actually, 
there was no sign of p-XSC-SM (data not shown), p-XSC uptake (Figure 14C) 
or cytotoxicity (Figure 14D) for the filtrate, suggesting the absence of SeC-SM.
Figure 14. Transformation of selenocompounds in cell culture medium
(A) Quantification of free p-XSC in complete DMEM medium without (black bar) or with 
(red bar) 1% extra BSA. N.D. refers to not detected. N = 3. (B) Forms of SeC in com-
plete medium and the filtrate. (C) C1498 cells (2×106 cells/mL) were treated with p-XSC 
(provided in complete medium or the filtrate) for 30 min. Intracellular Se level was then 
determined. N = 3. (D) C1498 cells (1×105 cells/mL) were treated with p-XSC (provided 
in complete medium or the filtrate) for 24 hr. Cell viability was then assayed using WST-1 
kit. N = 3. * indicates p ≤ 0.05 (Two-sided Mann-Whitney test).
Reprinted with permission from MDPI.
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4.3.2 Albumin reduces cellular uptake of selenocompounds
Since macromolecular SeC-BSA is canonically thought to enter cells less efficiently 
compared to free SeCs, we asked whether the presence of albumin could reduce 
cellular uptake of SeCs. C1498 cells were treated with SeC at the conditions when 
no cell death occurred (data not shown) to preclude free diffusion of SeC across cell 
membrane. Results demonstrate substantial increases of intracellular Se element 
upon treatment with p-XSC or ebselen in relative to basal level (Figure 15A). The 
increases were however abrogated by 1% extra BSA. We also characterized SeC 
uptake in FBS-free medium to exclude the effect of serum-derived albumin. In 
comparison to that in complete medium, SeC uptake in FBS-free medium increased 
by folds. Once again, adding extra BSA into FBS-free medium remarkably down-
regulated SeC uptake. In general, we observed that extracellular albumin content 
was inversely associated with intracellular Se level (Figure 15B).
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Figure 15. Effect of albumin on the cellular uptake of selenocompounds
(A) C1498 cells (2×106 cells/mL) were treated with p-XSC (10 µM) or ebselen (20 µM) 
for 30 min. The treatment was performed in complete medium (black), complete medium 
with 1% extra BSA (red), FBS-free medium (yellow), FBS-free medium with 1% extra 
BSA (blue). Intracellular Se level was then determined. N = 3. The red dash line marks 
the basal Se level from untreated cells. * denotes p ≤ 0.05 (Two-sided Mann-Whitney 
test). (B) Relationship between extracellular albumin content and intracellular Se content. 
Data were retrieved from panel A.
Reprinted with permission from MDPI and adapted.
4.3.3 Albumin antagonizes the efficacy of selenocompounds
Decreased exposure to SeCs in the presence of albumin would reasonably lead 
to lower cytotoxicity. In our experiments, we also found that co-treatment with 
1% BSA completely abolished the cytotoxicity of p-XSC in spite of the strong 
activity of p-XSC alone on murine C1498 cells (Figure 16A). Similar patterns 
were observed on two other human cell lines including HL60 (Figure 16B) and 
HUVEC (human umbilical vein endothelial cell; Figure 16C). In parallel, the 
cytotoxicity of ebselen, MeSeA or CysSe2 on C1498 cells was substantially 
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lower in the presence of 1% extra BSA (Figure 16D-16F). The antagonistic 
effect of albumin was also observed in FBS-free medium (Figure 16G-16H). 
In general, SeCs primarily form conjugates with albumin rather than react with 
small molecule thiols or remain unchanged. Due to the inferior uptake of the 
macromolecular SeC-albumin in relative to SeC itself, probably partially due to 
competitive inhibition by pristine albumin, intracellular Se pool and subsequent 
cell death was decreased.
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Figure 16. Effect of albumin on the cytotoxicity of selenocompounds
(A-C) Viability of C1498, HL60 or HUVEC cells after treatment with p-XSC. (D-F) Viability of 
C1498 cells after treatment with ebselen, MeSeA or CysSe2. The treatment was performed 
in appropriate complete medium for each cell line without (black) or with (red) 1% extra 
BSA. (G-H) Viability of C1498 cells after treatment with p-XSC or ebselen. The FBS-free 
medium was either without (yellow) or with (blue) 1% extra BSA. In all experiments, the 
treatment duration was 24 hr and cell viability was determined using CellTiter-Glo kit. Cell 
concentrations were 1×105/mL except for HUVEC. N = 4.
Reprinted with permission from MDPI and adapted.
37
4.4 Pharmacokinetics and Anti-leukemic effect of 
Selenocompounds in Mouse
On basis of the encouraging anti-leukemic efficacy in vitro and robust quantifica-
tion method established above, efforts was dedicated to exploring the pharmaco-
kinetic properties of SeCs and further examining their anti-leukemic efficacy in 
animal models.
4.4.1 Pharmacokinetics of selenocompounds in mouse
The four cytotoxic SeCs were administered intravenously, and similar concentration-
time curves were observed except for MeSeA which remained at very low level 
during the period examined (Figure 17A). The pharmacokinetic profile of p-XSC 
following intraperitoneal administration was also characterized. The preliminary 
therapeutic threshold was calculated based on the IC50 in vitro (≈ 1.5 µg/mL; 
Figure 7A) as well as the percentage of plasma volume in mouse blood (≈ 50%). 
The maximal concentration achieved was well below the therapeutic concentra-
tion threshold (~3 µg/mL; Figure 17B).
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Figure 17. Concentration-time curve of selenocompounds in mouse
SeC was administered intravenously (A) or intraperitoneally (B) and blood samples 
were taken at different time points. SeC concentration in plasma was then analyzed 
using RECID. The red line in panel B refers to the preliminary threshold of therapeutic 
potential. N = 3-5.
Reprinted with permission from Springer Nature.
38
Pharmacokinetic modeling of the concentration-time curves shows that p-XSC had 
lower clearance rate (5.8 mL/h) and conferred higher exposure (10.8 µg/mL·h) 
than the other three compounds following intravenous administration. For p-XSC, 
intraperitoneal route bestowed comparable drug exposure as intravenous route 
did (Table 5).
Table 5. Pharmacokinetic parameters of selenocompounds in mouse
One-compartment open model was used to calculate the parameters. N = 3-5.
Parameter CysSe2 
(5 mg/kg, iv)
MeSeA 
(5 mg/kg, iv)
Ebselen 
(2 mg/kg, iv)
p-XSC 
(2 mg/kg, iv)
p-XSC 
(2 mg/kg, ip)
AUC (µg/mL·h) 4.1 ± 1.1 N.A. 5.7 ± 0.7 10.8 ± 2.4 10.9 ± 2.2
Cmax (µg/mL) 20.4 ± 2.7 N.A. 18.1 ± 3.7 14.8 ± 2.7 1.0 ± 0.1
Cl (mL/h) 38.5 ± 11.7 N.A. 10.6 ± 1.3 5.8 ± 1.3 5.5 ± 1.1
Vss (mL) 7.5 ± 1.0 N.A. 3.4 ± 0.6 4.1 ± 0.8 N.A.
Note: N.A.: not available; AUC: area under the curve; Cmax: peak concentration; Cl: rate of clearance; Vss: 
apparent volume of distribution at steady state; iv: intravenous; ip: intraperitoneal. 
Reprinted with permission from Springer Nature.
4.4.2 p-Xyleneselenocyanate suppresses leukemia progression 
in mouse
p-XSC has poor aqueous solubility which hampered our attempts to increase the 
dose. In combination with its pharmacokinetic properties, we assume that intraperi-
toneal route might be unsuitable to confer adequate exposure. In the anti-leukemic 
study in mouse, we rationally chose tail vein as the route of administration.
The anti-leukemic activity of p-XSC in vivo was evaluated in a murine AML 
model which express luciferase reporter. Disease progression was non-invasively 
tracked using bioluminescence imaging (BLI). The treatment was started when the 
C1498-luc cells inoculated homed to bone marrow and continued for 5 successive 
days (Figure 18A). In the control group, disease progressed quickly and spread 
to common leukemia-affected organs including liver and bone marrow. In com-
parison, p-XSC-treated mice had significantly slower disease progression (Figure 
18B-18C). After dissection of bone marrow from mice sacrificed, less BLI signals 
were detected in p-XSC group (Figure 18D).
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Figure 18. Anti-leukemic effect of p-xyleneselenocyanate in mouse model
(A) Leukemia mice were established through inoculating 1×106 C1498-luc intravenously 
(day 0) and disease progression was monitored using IVIS system. p-XSC treatment 
(iv, 2 mg/kg) was performed during day 11-15 once daily. All mice were sacrificed at day 
22 and bone marrow from femur was collected. (B-C) Representative BLI images and 
quanti fication of whole body bioluminescence signal. Mann-Whitney test were used to 
compare the means between two groups. * denotes p ≤ 0.05. N = 6. (D) Representative 
heat maps of bioluminescence signal in bone marrow ex vivo.
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5 DISCUSSIONS
5.1 Stress Out Leukemia Cells
Using a panel of human and murine leukemia cell lines, we found that p-XSC 
was the most potent compound in eradicating leukemia cells among the six SeCs 
studied herein and also those reported elsewhere.140 Interestingly, p-XSC was 
found to quickly eradicate all the tested leukemia cells (Figure 7A), which might 
indicate high therapeutic efficacy and less likelihood for disease relapse. Previous 
studies reported that p-XSC generates superoxide anion through the one-electron 
transfer chemical process (Figure 5).141 Therefore, induction of oxidative stress is 
independent of particular enzyme/protein and may confer wide applicability, which 
could be an advantage over other therapies that target specific antigens, kinases or 
mutations. In line with this notion, we observed that the four leukemia cell lines, 
in spite of their distinct oncogene nature (BCR-BCL in K562 cells, C-MYC in 
HL-60 cells, and FOP2-FGFR1 in KG-1a cells), shared similar susceptibility to 
p-XSC (Figure 7B).
The toxicity of p-XSC on non-leukemia cells was observed at higher concentra-
tion, providing a therapeutic window for killing leukemia cells selectively. The 
superior vulnerability of leukemia cells to further oxidative stress is endowed by 
higher basal stress level in relative to that in normal cell. Huang et al. had set up 
an elegant model by transfecting oncogene in hematopoietic cells and found selec-
tive cytotoxicity of β-phenylethyl isothiocyanate (a ROS inducer) to oncologically 
transformed cells.81 In the present study, we used fibroblasts and endothelial cells 
instead of normal leukocytes as the controls. More conclusive evidences could be 
obtained if normal leukocytes were utilized.
As many other chemotherapeutic agents, the cytotoxicity of p-XSC was shown to 
be dependent on concentration and time (Figure 7A; Figure 9B), which was also 
demonstrated by the pattern how intracellular glutathione level changes (Figure 8D). 
One possible explanation might be the threshold of ROS that cellular antioxidative 
system could cope with. Take glutathione alteration as an example, in spite of an 
initial decrease following treatment with low-dose p-XSC (5 µM), glutathione 
became replenished later on. As a result, cellular viability remained unaffected. 
Once p-XSC-derived ROS exceeds the threshold, cell functions are irreversibly 
jeopardized and cell death commences. On the other hand, reinforcement of the 
antioxidative systems by supplementing the antioxidant NAC reasonably reduced 
the cytotoxicity of p-XSC (Figure 8C).
Mitochondria are canonical targets for oxidative damage probably because they 
are the major sources of endogenous ROS. In this study, we also found that 
p-XSC induced massive damages of mitochondria as early as 5 min after treat-
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ment (Figure 9A), suggesting the strong efficacy of p-XSC. Oxidative damages 
can initiate diverse cell death pathways dependent or independent on caspase. Our 
further analysis of pro-apoptotic factor and caspase corroborated that cell death 
might be independent of caspases (Figure 9C; Figure 9D). However, more studied 
are warranted to depict the complete pathway.
5.2 Towards More Selective Quantification
Our present results together with others’ have highlighted significant impacts of 
the chemical form and concentration on the efficacy of SeCs, making speciation 
and quantification of SeCs in biological matrices of high priority.121 However, the 
available methods, particularly for pharmacokinetic studies, are predominately 
measuring Se for a total elemental concentration. In this study, we combined 
hyphenated mass spectrometry and X-ray absorption spectroscopy for Se specia-
tion and established a general covalent binding model between cytotoxic SeCs 
and albumin, irrespective of physiochemical attributes in terms of structure and 
hydrophilicity (Figure 13A). Furthermore, we have developed a powerful quantifi-
cation method based on reductive cleavage and instant derivatization (RECID). The 
newly developed method enabled quantification of both free and  albumin-bound 
SeCs selectively and was applicable with good precision and accuracy to  biological 
samples including plasma.
Our data clearly show a correlation between cytotoxicity and albumin binding 
degree of SeCs (Figure 12B) as both are dependent on the intrinsic ability of 
SeCs to transform into selenol.133 In spite of the poor cytotoxicity of SeMet and 
MeSeCys, adding an appropriate lyase was reported to enhance their cytotoxic 
activities.87,141 Therefore, it is of high importance to keep in mind that albumin-
bound selenol should be considered while investigating the mechanism of action 
and/or tracing the active metabolites of SeCs. More broadly, emerging cytotoxic 
SeCs are presumably predisposed to bind to albumin and RECID could be used 
for the quantification as well.
In dynamic contexts like cells and blood circulation, downstream selenol metabo-
lites like methylselenol and hydrogen selenide might be present.142,143 The high 
reactivity of selenol per se leads to low abundance at steady state and challenges 
direct measurement. As RECID relies on (re)generation and instant stabilization of 
selenol intermediates, it might be used for quantification of other selenol metabolites 
beyond the selenol form of parent compounds. Accordingly, depiction of a clearer 
metabolic pathway could be envisioned. On the other hand, it should be mentioned 
that several methods should be combined in order to establish the original forma-
tion pathway of selenol. Since albumin is present in various biological matrices 
(e.g. cell culture medium, tissue homogenate, cell lysate and plasma), we believe 
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that albumin binding prevails and ubiquitously interferes with quantification of 
SeCs. Accordingly, the application of RECID could be broadened from plasma 
to many other biological contexts.
5.3 Albumin, an Overlooked Key Cofounder
Albumin is ubiquitously present in biological contexts, while its critical role in 
the determination of SeCs cytotoxicity is firstly reported in the present investiga-
tions. In fact, albumin content varies among the cell culture media in common use 
(ranged 0.1-0.4%) and is as high as 3-5.5% in the plasma of laboratory animals and 
human. Such variability might account for the widely reported heterogeneity in 
cytotoxicity and alert potential discrepancies in translational studies. Furthermore, 
albumin level in patients might fluctuate dramatically depending on the patho-
physiological conditions, which can in turn determine the treatment efficacy as 
well as adverse effects of SeCs.
Albumin is widely reported to have anti-oxidative function executed through “free 
radical-trapping” and “ligand-binding”, 144 in contrast to the pro-oxidant SeCs. 
Considering the ubiquitous presence of the antioxidative system as well as other 
cellular components, we assumed that the strong antagonistic effect of albumin 
is unlikely due to trapping of free radical intracellularly. In other words, albumin 
was supposed to bind SeCs extracellularly and downregulate subsequent cellular 
uptake and cytotoxicity. In consistence, measurements of intracellular Se demon-
strated an inverse relationship between extracellular albumin content and cellular 
uptake of SeCs (Figure 15B).
Since addition of albumin could decrease SeCs uptake, we assume that other bio-
logical and/or pharmacological functions of SeCs besides the cytotoxicity, like 
antimicrobial activity, might be similarly antagonized. From the therapeutic per-
spective, preclusion of albumin binding through controlled release of SeCs from 
nanomaterial or prodrug in combination with targeting moiety could probably 
improve the efficacy. This notion necessitates further exploration in vitro and in vivo.
SeCs formed macromolecular conjugates with albumin, while the uptake mecha-
nism of the conjugate is not fully understood but might involve albumin scavenger 
receptors on basis of the competitive inhibition phenomenon.145,146 Early studies 
had found tumor-specific distribution of Se and utilized selenite as radiotracer 
for tumor detection.113 Our study might provide a mechanistic perspective that 
formation of SeC-albumin conjugate in vivo directs SeC to tumors that have high 
demand for albumin.147 In this sense, exploitation of albumin scavenger receptors 
might impact uptake and subsequent functions of SeCs.
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Noteworthy, 10 µM of p-XSC in complete medium was all in form of p-XSC-
BSA and eradicated leukemia cells (Figure 7A; Figure 14A), indicating that the 
SeC-albumin conjugate is still internalized by the cells and biologically functional. 
This is in agreement with the systemic toxicity of SeCs in animals and human 
despite that the albumin content in circulation is even higher than the maximal 
concentration examined in the present studies (2.2%-5% vs 1.2%). Even though 
both free SeCs and SeC-BSA could be internalized, it is unclear regarding the 
relative contribution of each form in the overall cellular uptake and cytotoxicity. 
The functions of SeC-albumin also stress the importance of quantification of both 
the free form as well as the albumin-bound fractions.
In addition to albumin, other thiols like GSH and Cys that might participate in SeCs 
transformation.135 However, our results indicated the absence of small-molecule 
conjugates in either fresh or conditioned cell culture medium, highlighting a 
predominant role of albumin in SeCs transformation. The superior reactivity of 
albumin might be attributed to Cys34 residue as well as high concentration in 
common biological matrices. A previous study by Olm et al. demonstrated that 
extracellular Cys could increase the uptake and cytotoxicity of selenite,116 which 
seemingly contrasts with our finding. The disagreement might be due to the 
stepwise transformation of selenite: 1) reduction into more reduced forms (e.g. 
selenodiglutathione) in the presence of Cys; 2) binding to albumin. Therefore, the 
facilitator role of Cys in selenite uptake probably originates from its action on the 
former transformation step. Moreover, the study of Olm et al. did not specifically 
consider the effect of albumin.
5.4 Promises and Challenges in Treating Leukemia 
Mouse
The strong albumin binding property and importance of albumin-bound fraction 
underline the essentiality to quantify total SeCs. Using the newly established 
method, we depicted the pharmacokinetic properties of four diverse SeCs, for the 
first time (Figure 17). Ebselen and p-XSC are both highly lipophilic and should 
theoretically have large distribution volume in vivo. To our surprise, their distribution 
volume was close to blood volume in adult mouse (3.4-4.1 mL vs 2 mL; Table 5), 
supporting significant specie transformation. Secondly, due to the fact that the four 
SeCs all have strong affinity to albumin, their pharmacokinetic properties were 
assumed to resemble mouse albumin. On the contrary, rather unique pharmaco-
kinetic properties were observed, particularly in case of MeSeA (Figure 17A). We 
also found that the half-life of the studied SeCs was much shorter compared to I131-
labelled mouse albumin (< 30 min vs 21 hr). Likely, SeC-albumin conjugate was 
more quickly eliminated by albumin scavenger receptors. However, this suspicion 
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requires further investigation. Apparently, more studies are warranted to delineate 
how albumin binding impacts ADME (absorption, distribution, metabolism and 
excretion) of different SeCs.
Since p-XSC was the most potent against leukemia cell in vitro and also had the 
highest exposure following intravenous administration, it was selected for treating 
leukemia mouse. The pharmacokinetic profile after intraperitoneal administration 
was also examined with the aim to optimize treatment regimen. However, the maxi-
mum concentration reached was well below the therapeutic concentration obtained 
from preliminary experiments (Figure 17B; Table 5). Thus, in later stage p-XSC 
was administered intravenously. The experiences further underline the importance 
of a proper analytical method as well as thorough pharmacokinetic investigation.
The treatment was started when C1498-luc cells homed into the bone marrow. 
Significant delay in disease progression following the p-XSC treatment was 
observed in comparison to the control group. The treatment efficacy was observed as 
well in the bone marrow. However, we believe that extension of treatment duration 
and increase the dose of p-XSC will significantly improve the therapeutic efficacy.
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6 CONCLUSIONS
In the present thesis, we explored one group of the most redox-active agents, 
selenocompounds, for leukemia treatment. Among the six selenocompounds 
tested, p-xyleneselenocyanate (p-XSC) displayed remarkable cytotoxicity against 
leukemia cells through induction of oxidative stress. The cytotoxic activity was 
critically concentration- and time-dependent. Following p-XSC treatment,  massive 
mitochondria damage and release of apoptosis-inducing factor were observed.
In pursuit of the pharmacokinetic properties for in vivo application, we observed 
that cytotoxic selenocompounds could transform into selenol intermediates and 
react with albumin thiols through selenium-sulfur bond. Accordingly, a  selective, 
reproducible and robust method that measures both free and albumin-bound 
seleno compounds was established and enabled pharmacokinetic investigations.
Moreover, we found that albumin binding not only occurred in plasma but also in 
cell culture media. The macromolecular conjugate between selenocompounds and 
albumin was less internalized compared to free compounds, leading to reduced 
drug exposure intracellularly. As a result, the cytotoxicity of selenocompounds 
was antagonized by extracellular albumin.
Using the newly developed analytical method, we found that intraperitoneal 
administration of p-XSC would not reach the preliminary therapeutic threshold 
as established from cytotoxicity experiments in vitro. p-XSC was therefore intra-
venously administrated and shown to significantly postpone leukemia progression 
in the mouse model.
In general, this thesis proved that redox-active selenocompounds could be used 
for leukemia treatment and in the meanwhile provided that albumin content was 
a critical factor in determining the therapeutic efficacy.
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7 FUTURE PERSPECTIVES
Firstly, the vulnerability of leukemia cells to p-XSC treatment in relative to non-
leukemia cells was still low as shown by the small difference in the IC50s. Future 
endeavors should be devoted to expanding the therapeutic window and improv-
ing the selectivity of selenocompounds. One potential strategy would be search-
ing for particular cancer subtypes that have defects in antioxidative system.148-150 
Alternatively, it would be worthy combining another strategy of selectivity. For 
instance, when the ROS inducer β-lapachone was combined with poly (ADP-
ribose) polymerase inhibitors, cytotoxicity that is more selective was achieved.151
Secondly, our studies suggested that the overall cytotoxicity of selenocompounds 
partially originates from the SeC-albumin conjugate, but it remains unclear regard-
ing the exact contribution of the conjugate in relative to that observed for the 
free compound. For free selenocompounds, the internalization efficiency could 
be correlated to hydrophobicity thereof; however, for SeC-albumin, that was not 
investigated in the present study. To address this question, it would be helpful 
to investigate different SeC-albumin conjugates that have the same Se level per 
molecule as well as absolute absence of albumin.
Thirdly, the antagonistic effect of albumin on the efficacy of selenocompounds is 
believed to prevail in different conditions. Preclusion of albumin binding through 
controlled release of SeCs from nanomaterial or prodrug could probably improve 
the efficacy. This might in parallel resolve the limitation regards poor solubility 
of selenocompounds, particularly p-XSC.
The last but not the least, even though p-XSC could eradicate leukemia cells in 
vitro, disease progression and persistence of leukemia lesion in bone marrow 
were still noticed in the mouse model. To achieve better therapeutic strategies 
in hematological malignancies, increasing the distribution of p-XSC into highly 
resistant microenvironment, like the bone marrow niche, might be one of the future 
directions. In addition, although the superoxide anion generated by p-XSC could 
be transformed into more reactive hydroxyl radicals by endogenous chaperones, 
it would be interesting to explore whether loading p-XSC into a well-designed 
targeted nanocarriers where Fenton reaction occurs could potentiate the treatment 
efficacy or not.
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